Core Viewpoint - Protalix BioTherapeutics, Inc. will release its financial results for the quarter ended June 30, 2025, and provide a business and clinical update on August 14, 2025 [1] Group 1: Financial Results and Conference Call - The management will host a conference call to discuss the financial results and provide updates on recent corporate and regulatory developments [2] - The conference call is scheduled for August 14, 2025, at 8:30 a.m. EDT [3] Group 2: Webcast and Participation Details - The conference will be webcast live from the Protalix website, and participants are encouraged to access the call at least 15 minutes early [4] - A replay of the call will be available for two weeks on the Events Calendar of the Company's website [4] Group 3: Company Overview - Protalix is focused on the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system [5] - The company has FDA approval for its first product, taliglucerase alfa, for the treatment of Gaucher disease, and its second product, Elfabrio®, was approved in May 2023 [5][6] - Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [6]